LOGIN  |  REGISTER
C4 Therapeutics

Cadrenal Therapeutics (NASDAQ: CVKD) Stock Quote

Last Trade: US$0.61 -0.03 -4.69
Volume: 52,618
5-Day Change: 1.67%
YTD Change: -17.56%
Market Cap: US$9.770M

Latest News From Cadrenal Therapeutics

PONTE VEDRA, Fla. , March 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with rare cardiovascular conditions, today provided a corporate update in connection with the filing of its Annual Report on... Read More
PONTE VEDRA, Fla. , Feb. 26, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced its participation at the upcoming Technology and Heart Failure... Read More
PONTE VEDRA, Fla. , Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply... Read More
PONTE VEDRA, Fla. , Jan. 31, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, cited today a recent peer-reviewed article in the Journal of the American College of Cardiology (JACC) titled, "When Direct Oral Anticoagulants Should Not Be Standard Treatment" by... Read More
PONTE VEDRA, Fla. , Jan. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain conditions, announced today that Douglas Losordo , M.D., Chief Medical Officer of Cadrenal, will participate in a... Read More
PONTE VEDRA, Fla. , Jan. 4, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain conditions, announced today that the Company will present at Biotech Showcase™ 2024, alongside the J.P. Morgan 42... Read More
PONTE VEDRA, Fla. , Dec. 19, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain orphan diseases, today announced that Noble Capital Markets ("Noble") has initiated equity research coverage on... Read More
PONTE VEDRA, Fla. , Dec. 12, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage, novel, oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths (due to blood clots in patients with certain orphan diseases), today announced an engagement with The Sage Group ( www.sagehealthcare.com ) to assist the... Read More
PONTE VEDRA, Fla. , Nov. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham , CEO, will present at NobleCon19 - Noble Capital... Read More
PONTE VEDRA, Fla. , Nov. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) ("Cadrenal Therapeutics" or the "Company") a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection... Read More
PONTE VEDRA, Fla. , Oct. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, announced today that Quang Pham , CEO, will be participating in a Company Webcast and... Read More
Tecarfarin is the only known Novel Vitamin K Antagonist in Development PONTE VEDRA, Fla. , Sept. 5, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today cited recent... Read More
NEW YORK , Aug. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced the expanded evaluation of tecarfarin for the treatment of patients with antiphospholipid... Read More
PONTE VEDRA, Fla. , Aug. 28, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today announced that its Founder, Chairman, and CEO Quang Pham ; CFO Matthew Szot ; and CMO, Dr.... Read More
PONTE VEDRA, Fla. , Aug. 10, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients with certain rare medical conditions, today provided a corporate update in connection with the filing of its Quarterly Report on Form... Read More
PONTE VEDRA, Fla. , Aug. 1, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that the Company is expanding its focus for tecarfarin to patients with implanted medical devices for heart diseases who are struggling with the lack... Read More
PONTE VEDRA, Fla. , July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees. Lisicki brings... Read More
PONTE VEDRA, Fla. , July 14, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , ("Cadrenal" or the "Company") (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that it has closed its previously announced private placement with an institutional investor for the issuance and sale of... Read More
PONTE VEDRA, Fla. , July 12, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , ("Cadrenal" or the "Company") (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that it has entered into a securities purchase agreement with certain institutional investors for the issuance and sale of... Read More
PONTE VEDRA, Fla. , June 1, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Cadrenal or the Company) (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, announced today that the company will participate in investor and partnering meetings at the BIO International Convention being held June 5-8, 2023 in... Read More
PONTE VEDRA, Fla. , May 10, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with today's filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 . Recent Highlights In January 2023 , U.S.... Read More
PONTE VEDRA, Fla. , May 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today that Quang Pham , CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023.... Read More
PONTE VEDRA, Fla. , March 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2022 . Recent Highlights U.S. Food and Drug... Read More
Tecarfarin, a novel therapy designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with End Stage Renal Disease and Atrial Fibrillation, may be a new treatment option for this underserved patient population PONTE VEDRA, Fla. , March 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage... Read More
Cue Biopharma

COPYRIGHT ©2023 HEALTH STOCKS HUB